{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:17:42Z","timestamp":1777889862291,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmcl.2026.130652","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:29:17Z","timestamp":1775604557000},"page":"130652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer"],"prefix":"10.1016","volume":"137","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadirya","family":"Asan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130652_bb0005","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.biopha.2017.11.065","article-title":"HDACis (class I), cancer stem cell, and phytochemicals: cancer therapy and prevention implications","volume":"97","author":"Bayat","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2026.130652_bb0010","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2026.130652_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteins modulates cellular signalling at multiple levels","volume":"41","author":"Spange","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130652_bb0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/sj.embor.embor941","article-title":"Regulating histone acetyltransferases and deacetylases","volume":"4","author":"Legube","year":"2003","journal-title":"EMBO Rep"},{"key":"10.1016\/j.bmcl.2026.130652_bb0025","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.2174\/0929867326666190712160842","article-title":"Histone deacetylases (HDACs) in gastric cancer: an update of their emerging prognostic and therapeutic role","volume":"27","author":"Schizas","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2026.130652_bb0030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/epi.3.6.7273","article-title":"The role of histone deacetylases in prostate cancer","volume":"3","author":"Abbas","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.bmcl.2026.130652_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/epi.3.1.5736","article-title":"HDACs and HDAC inhibitors in colon cancer","volume":"3","author":"Mariadason","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.bmcl.2026.130652_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/OTT.S93528","article-title":"Chidamide in the treatment of peripheral t-cell lymphoma","volume":"10","author":"Chan","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bmcl.2026.130652_bb0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1358\/dot.2017.53.3.2595452","article-title":"Chidamide tablets: HDAC inhibition to treat lymphoma","volume":"53","author":"Xu","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bmcl.2026.130652_bb0050","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/1871520616666160901150427","article-title":"Preclinical and clinical studies of chidamide (CS055\/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy","volume":"17","author":"Gao","year":"2017","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.bmcl.2026.130652_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130652_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130652_bb0065","article-title":"Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world multicenter study","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.bmcl.2026.130652_bb0070","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.21037\/tcr-23-2169","article-title":"Molecular, biological characterization and drug sensitivity of chidamide-resistant MCF7 cells","volume":"13","author":"Dai","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130652_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","article-title":"Bromodomains: structure, function and pharmacology of inhibition","volume":"106","author":"Ferri","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130652_bb0080","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130652_bb0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130652_bb0090","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130652_bb0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130652_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bcp.2016.08.009","article-title":"Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1","volume":"117","author":"Zhang","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130652_bb0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/adt.2024.109","article-title":"Roadmap to cytotoxicity: exploring assays and mechanisms","volume":"23","author":"Shekhawat","year":"2025","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.bmcl.2026.130652_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-1759(86)90215-2","article-title":"Use of MTT colorimetric assay to measure cell activation","volume":"94","author":"Gerlier","year":"1986","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bmcl.2026.130652_bb0115","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1038\/s41596-021-00615-0","article-title":"Analysis of clonogenic growth in vitro","volume":"16","author":"Brix","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmcl.2026.130652_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33665","article-title":"Flow cytometry-based quantitative analysis of cellular protein expression in apoptosis subpopulations: a protocol","volume":"10","author":"Alshehade","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bmcl.2026.130652_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109966","article-title":"Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1\u03b1 expression in non-small cell lung carcinoma","volume":"361","author":"Fu","year":"2022","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.bmcl.2026.130652_bb0130","article-title":"USP5 inhibition suppresses head and neck squamous cell carcinoma progression via EMT pathway regulation","volume":"102459","author":"Asan","year":"2026","journal-title":"Gene Reports"},{"key":"10.1016\/j.bmcl.2026.130652_bb0135","article-title":"The oncogenic role of TRIP13 in clear cell renal cell carcinoma and the synergistic inhibitory effect of combined DCZ0415 and TI17 therapy","volume":"102336","author":"Wang","year":"2025","journal-title":"Gene Reports"},{"key":"10.1016\/j.bmcl.2026.130652_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125584","article-title":"Improvement in transient agarose spot (TAS) cell migration assay: microplate-based detection and evaluation","volume":"26","author":"Veres-Szekely","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130652_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202502267","article-title":"A Novel Ribociclib Derivative Targeting p53-Mediated Apoptosis and Inhibition of Tumor Growth in Breast Cancer","volume":"23","author":"Zhang","year":"2026","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.bmcl.2026.130652_bb0150","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/acsmedchemlett.2c00272","article-title":"Fragment-based discovery of a novel, brain penetrant, orally active HDAC2 inhibitor","volume":"13","author":"Tamanini","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130652_bb0155","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J Chem Inf Model"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:23:27Z","timestamp":1777613007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0960894X26001198"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130652","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130652"}}